Лимфогранулематоз и лимфомы: литература
Abrey LE, Yahalom J, and DeAngelis LM. Treatment of primary CNS lymphoma. J clin Oncol 2000, 18:3144.
Aleman BMP, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348:2396.
Armitage JO, et al. New approaches to classifying nonHodgkin lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998; 16:2780.
Browne WB, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999; 85:706.
Canellos GP, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.
Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235.
Czuzman MS,et al. Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268.
Daum S, et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on intestinal non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:2740.
DeAngelis LM. Primary central nervous system lymphoma: a curable brain tumor. J Clin Oncol 2003; 21:4471.
Diehl V, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386.
Dores GM, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20:3484.
Ferreri AJM, et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003; 21:2407.
Hasenclever D, et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339:1506.
Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissue. Lyon, France: IARC, 2001.
Khouri IF, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16:3803.
Loeffler M, et al. Dose response relationship of complementary radiotherapy following 4 cycles of combination chemotherapy in intermediate stage Hodgkin's disease. J Clin Oncol 1997; 15:2275.
Lundin J, et al. Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of Campath-1H Treatment in Low Grade NHL. J Clin Oncol 1998; 16:3257.
Magrath I, et al. Adults with small non-cleaved cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14:925.
McLaughlin Р, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four dose treatment program. J Clin Oncol 1998; 16:2825.
Philip T, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540.
Rosenwald A, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse laige-B-cell lymphoma. N Engl J Med 2002; 346:1937.
Wilson WH, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol 2002; 1 (Suppl 2):41.
Witzig ТЕ, et al: Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453.
Смотрите также:
